top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hRANKL mice
Strain Name
C57BL/6-Tnfsf11tm1(TNFSF11)Bcgen/Bcgen
Common Name  B-hRANKL mice
Background C57BL/6 Catalog number  111072
Aliases 
CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2, sOdf
NCBI Gene ID
21943

Protein expression analysis


from clipboard


Strain specific RANKL expression analysis in wild-type C57BL/6 mice and homozygous B-hRANKL mice by flow cytometry. CD4+ T cells were isolated from the spleen of wild-type C57BL/6 mice (+/+) and homozygous B-hRANKL mice (H/H) stimulated with anti-mCD3e and anti-mCD28 antibodies in vitro. Mouse RANKL was detectable only in wild-type C57BL/6 mice. Human RANKL was exclusively detectable in homozygous B-hRANKL mice.


mRNA expression analysis



Strain specific analysis of RANKL gene expression in wild-type C57BL/6 mice and B-hRANKL mice by RT-PCR. Mouse Rankl mRNA was detectable only in thymocytes of wild-type C57BL/6 mice (+/+). Human RANKL mRNA was detectable only in homozygous B-hRANKL mice but not in wild-type mice. 


Analysis of leukocytes cell subpopulation in spleen


from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hRANKL mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hRANKL mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hRANKL in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.


Analysis of T cell subpopulation in spleen

from clipboard


Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hRANKL mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hRANKL mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hRANKL in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.


Analysis of leukocytes cell subpopulation in lymph node

from clipboard


Analysis of lymph node leukocyte subpopulations by FACS. Lymph nodes were isolated from female C57BL/6 and B-hRANKL mice (n=3, 6-week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells and NK cells in homozygous B-hRANKL mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hRANKL in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.


Analysis of T cell subpopulation in lymph node

from clipboard


Analysis of lymph node T cell subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hRANKL mice (n=3, 6-week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hRANKL mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hRANKL in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.


Analysis of leukocytes cell subpopulation in blood

from clipboard


Analysis of blood leukocyte subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hRANKL mice (n=3, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hRANKL mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hRANKL in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in blood. Values are expressed as mean ± SEM.


Analysis of T cell subpopulation in blood

from clipboard


Analysis of blood T cell subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hRANKL mice (n=3, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hRANKL mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hRANKL in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in blood. Values are expressed as mean ± SEM.


Analysis of  mTRAcP-5b concentration in plasma

Strain specific mouse TRAcP-5b concentration in homozygous B-hRANKL mice by ELISA. Plasma was collected from wild-type C57BL/6 mice (+/+) and homozygous B-hRANKL mice (H/H) and analyzed by ELISA with TRAcP-5b ELISA kit. (n=3, 7-week-old or 16-week-old).  Concentration of mouse TRAcP-5b in B-hRANKL mice was similar to that in wild-type mice. Values are expressed as mean ± SEM.


Antibody binding assay


from clipboard


Antibody binding analysis of B-hRANKL mice by FACS. CD4+ T cells were collected from wild-type C57BL/6 mice (+/+)  and homozygous B-hRANKL mice (H/H). Single live cells were gated for CD4+ population and used for further analysis. Anti-hRANKL antibody denosumab (in house) can bind CD4+ T cells of B-hRANKL mice, but not bind the cells of wild-type C57BL/6 mice. 

In vivo efficacy of anti-human RANKL antibody with mouse osteoporosis model 

from clipboard

The use of an anti-human RANKL antibody denosumab (in house) in an osteoporosis mouse model in B-RANKL mice was effective in improving several key measures of osteoporosis. Mice were first randomly separated to receive ovariectomy or sham surgery. The ovariectomized mice were then randomly divided into 3 treatment groups (OVX, Denosumab and PTH1-34) at 4 weeks after surgery (n = 6). Mice were sacrificed at 4 weeks after treatment. Serum was obtained 3 times before and after treatment for analysis of C terminal telopeptide of type 1 collagen (CTX-1) and osteocalcin (OC). The time points of serum collection were shown in figure A. The proximal tibia were harvested for analysis of bone mineral density (BMD) by μCT. A-B. The concentration of serum bone resorption marker CTX-1 and serum bone formation marker OC. C. Representative micro-CT images of the proximal tibia in each group. D. The BMD change of the proximal tibia. Results showed that compared with the sham group without surgery, the concentration of bone resorption marker CTX-1 was significantly increased, while the concentration of bone formation marker OC and BMD change of proximal tibia were significantly decreased in the OVX group, indicating that the osteoporosis mouse model was successfully modeled with B-hRANKL mice. After treatment with anti-human RANKL antibody or PTH, the concentration of CTX-1 was significantly decreased, while the concentration of OC and the percentage change of BDM were significantly increased compared with the untreated OVX group. These results indicated that the anti-human RANKL antibody could effectively treat osteoporosis in B-hRANK mice. The B-hRANKL mice provide a powerful preclinical mouse model for in vivo evaluating efficacy of anti-human RANKL antibodies. Values are expressed as mean ± SEM.